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Abstract: Use of injectable volume replacement products has increased dramatically in the US 
in recent years. An optimal outcome with volume replacement depends on a thorough   knowledge 
of the products on the part of the dermatologic/aesthetic physician specialist, identification 
of patients with a likelihood of benefiting from volume replacement procedures, selection of 
an appropriate product for the individual patient, and effective patient counseling to ensure 
adherence to posttreatment care instructions. Adherence to physician instructions in the field 
of dermatology appears limited, and there is very little published information on adherence to 
physician instructions following facial volume replacement procedures. The purpose of this 
review is to provide strategies for understanding and overcoming the barriers to adherence 
with the widely used dermal fillers. Strategies include using patient-centered techniques, such 
as a motivational interview encouraging the patient to follow postprocedure care instructions, 
eg, massage. In this case, demonstrating massage techniques while the patient is still in the 
office, with patient participation and detailed feedback, also contributes to good adherence with 
posttreatment care instructions. Telephone counseling, reminder postcards, and text messages 
may help improve clinic attendance for follow-up. Motivated patients who demonstrate good 
  adherence to physician instructions generally respond well to volume replacement treatments, and 
usually experience fewer adverse events than patients who do not follow instructions. Although 
promoting adherence to pretreatment and posttreatment protocols remains a challenge, patient 
counseling throughout the treatment process can lead to successful results.
Keywords: improving adherence, injectable volume replacement, product selection,   rejuvenation 
procedure, soft tissue augmentation
Introduction
The use of injectable volume replacement products in facial rejuvenation procedures 
has increased dramatically in the US in recent years.1 An optimal outcome from a 
rejuvenation procedure depends on a thorough knowledge of the products and their 
injection techniques on the part of the dermatologic/aesthetic physician specialist, 
identification of patients with a likelihood of benefiting from volume replacement 
procedures, selection of an appropriate product for the individual patient, and 
  effective patient counseling.2 Adherence to a treatment protocol may be defined 
as the patient following treatment instructions provided by her/his physician; it is 
known that   failure to do so can result in wasted resources and may cause increased 
morbidity and mortality.3–5 Individualized counseling for each patient, based on 
treatment selection, is paramount for improving adherence and achieving success-
ful outcomes. This review discusses the barriers to adherence and strategies for Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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  overcoming them, as well as the prerequisites for successful 
outcomes in patients treated with injectable dermal fillers. 
It also provides an overview of widely used dermal fillers, 
and suggests strategies that may be helpful for physicians 
to adopt when counseling patients to enhance their adher-
ence and treatment success.
Barriers to patient adherence
Limited patient adherence to physician instructions is wide-
spread in dermatology,4,6 suggesting that patients may be 
more likely to adhere to medication regimens than to behavior 
changes.3 Adherence may be influenced by demographic fac-
tors, education level, and socioeconomic status,5 the presence 
of comorbidities requiring medication that cannot readily be 
discontinued for the procedure,7,8 and psychiatric disorders, 
such as depression and anxiety.5 Furthermore, logistic issues, 
such as a long wait for a follow-up appointment, can reduce 
adherence.9
Communication barriers are also known to limit 
adherence.5,10,11 According to a meta-analysis of a large 
number of clinical trials and experimental interventions 
across a range of therapeutic areas, poor communication 
leads to a 19% greater risk of poor adherence or non-
adherence.11 Extrapolating from the number of medical 
office visits made in the US in 2005, the authors of this 
meta-analysis estimated that stronger physician interper-
sonal communication skills could have led to improved 
adherence in more than 183 million office visits that 
year.11 Perhaps the most obvious communication barrier 
is when a patient who does not speak the same language 
as the physician; the absence of a translator and the lack 
of translated written instructions present challenges that 
may impact adherence.10 Even when a patient speaks the 
same language, it is important for the physician to avoid 
making assumptions about the patient’s baseline knowledge 
and understanding of the situation,5 and to conduct patient 
counseling sessions accordingly.
Strategies for improving  
patient adherence
A trusting patient-physician relationship fosters adherence 
to pretreatment and posttreatment protocols.2,4,6,12 Addition-
ally, counseling patients about the importance of adherence 
during the initial consultation and at each follow-up visit 
can be beneficial.13 Physicians can also use patient-centered 
techniques, such as motivational interviewing, to encourage 
self-management.14 Motivational interviewing facilitates 
discussion about self-care practices in a nonjudgmental 
atmosphere and helps patients integrate these practices into 
their schedules.14 For example, during counseling sessions the 
physician might ask open-ended questions, such as, “What 
do you see as the benefits of adhering to your posttreatment 
instructions?” and “Thinking about your typical day, how 
might you find time to massage the treated area?” Tele-
phone counseling can also promote treatment adherence.15 
Telephone calls, reminder postcards, and text messages 
can improve attendance at follow-up visits9,16 and provide 
additional opportunities for further counseling throughout 
patient treatment. For example, automated telephone remind-
ers significantly improve adherence in patients who require 
repeat mammography.17
In the management of glaucoma, patient education has 
been found to be helpful in improving adherence,18 although 
studies of this issue have proven difficult.19 However, tech-
niques for communication appear to extend beyond patient 
education with printed material;20 if using this format, the 
text should meet certain guidelines for clarity.21
A large meta-analysis across multiple therapeutic areas 
has shown that while it is possible to demonstrate improved 
adherence to medication instructions, there may be little 
impact on clinical parameters.22 Furthermore, the authors 
suggest that simplification of dosing, monitoring, and feed-
back, and providing information over a number of counseling 
sessions, may be effective.22 Although the applicability of 
these findings to patients undergoing soft tissue rejuvena-
tion is unknown, there could be benefits in utilizing some 
of the counseling strategies to help achieve better patient 
adherence.
For example, the demonstration of after-care techniques 
while the patient is still in the office is an effective means 
of encouraging posttreatment self-care and adherence. Such 
demonstrations can include, after positioning a mirror to 
maximize the patient’s field of vision, a review of appropriate 
massage techniques, with patient participation to help review 
the correct techniques, and to reinforce the importance of 
posttreatment self-care with the patient.
Prerequisites for successful  
patient outcomes
Achieving a successful outcome in soft tissue augmentation 
is multifactorial. The training and experience of the physician 
with the procedures and products are particularly important, 
but effective counseling during screening of the patient and 
selection of the appropriate product to use will also have an 
impact on the outcome. Finally, careful follow-up by the 
patient is essential in reducing the risk of adverse events Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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(AEs). Each element is discussed in more detail in the 
  following sections.
Physician training
Dermatologic/aesthetic physician specialists need to receive 
in-depth training before using soft tissue augmentation 
products.2,23 In addition to being familiar with the prescribing 
information and peer-reviewed literature for an agent, physi-
cians should have observed the administration of the product 
by a trained expert before using the product themselves.2 It is 
advisable for physicians who are starting to use dermal fillers 
to gain experience with temporary fillers before incorporat-
ing long-term and permanent fillers in their practice.24 This 
approach also ensures that patients are satisfied with the scope 
of their planned augmentation procedures. Understanding 
the depth at which the various products should be placed is 
particularly important.2,24
Patient counseling and pretreatment 
screening
Effective patient screening during the initial consultation is 
a prerequisite for successful facial soft tissue augmentation 
procedures.25 Appropriate candidates for soft tissue aug-
mentation are individuals who demonstrate, after discussion 
with the physician, an understanding of the nature of dermal 
filling procedures, realistic expectations about aesthetic 
outcomes, a commitment to assist with their pretreatment 
and posttreatment care, and a willingness to schedule and 
attend follow-up examinations and additional or touch-up 
treatments as necessary.2 It is important that patients explain 
their motivation for having the procedure (eg, achieving 
a long-lasting rather than an immediate improvement in 
appearance). This allows physicians to recommend products 
consistent with patient objectives and to provide an overview 
of the pretreatment and posttreatment care the patient should 
follow for optimal results.
The physician should also review and discuss the 
patient’s full medical history, including current prescription 
and over-the-counter medication use.2 If approved by the 
primary care physician, nonessential aspirin, nonsteroidal 
anti-inflammatory agents, and vitamin/herbal supplements 
that have anticoagulant effects should be discontinued 
10 days before treatment to minimize the risk of bruising 
and swelling.7,8 Patients with active skin inflammation or 
infection in or near the proposed treatment area should be 
advised to defer treatment until the inflammatory or infec-
tious process has been controlled.26–28 Finally, prophylactic 
antiviral and/or antibacterial therapy should be considered 
for patients who are susceptible to infection or have a history 
of herpes simplex viral infections.29
Patient counseling and product selection
The soft tissue augmentation product that meets the patient’s 
overall objectives is often identified in the pretreatment 
counseling session, during which the benefits and limitations 
(including the AE profile) of the various devices are fully 
discussed. Some patients prefer the hyaluronic acids because 
they perceive these injectables to be more natural, whereas 
others choose products with longer-lasting results. Still others 
may have their decision influenced by cultural and percep-
tual factors (eg, preference not to use a product of bovine 
origin). Moreover, the patient’s history of allergic reactions 
may further eliminate some products from consideration. For 
some patients, cost may be an important factor in product 
selection, influencing the number of treatment sessions that 
can be planned and the intervals between them.
Again, during pretreatment counseling, it is important for 
the physician to have an open dialog with the patient (ask 
questions about the patient’s goals, expectations, and reasons 
for the cosmetic procedure) and to determine clinically the 
area and extent of volume loss requiring correction; this will 
help narrow the range of options that need to be discussed 
in detail. Some clinicians may also recommend that patients 
begin dermal filler therapy with a shorter-acting agent so that 
they can decide whether they like the effects of treatment 
before committing themselves to a long-term approach.30,31
Posttreatment follow-up
Because each patient has different needs, and each product 
has different requirements, it is important for physicians to 
individualize their approach to posttreatment counseling. 
Posttreatment patient care and follow-up requirements can 
play a key role in product selection. Repeating information 
relating to time commitment and adherence requirements 
after treatment will reinforce the relevant information 
necessary to ensure adherence. The physician should also 
stress the importance of adherence to posttreatment care as 
it relates to specific products so that the patient understands 
the differences between the available options and to ensure 
he or she can commit to the follow-up treatment needed to 
achieve the patient’s desired results.
In general, exposure of the treated area to excessive sun, 
heat, and ultraviolet light from lamps should be minimized 
for approximately 24 hours or until any initial swelling 
and erythema have resolved.26,27 An ice or cold pack can 
be used to minimize tenderness, swelling, and bruising Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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  following instruction from the physician on how to apply it.26 
Patients should also be instructed to report any AEs, other 
than mild local reactions, to their physician.
Overview of dermal fillers
Dermal fillers may be categorized by their duration of action 
as short-acting, long-acting, or permanent products. Their 
characteristics are summarized in Table 1.29 Short-acting 
products (collagens, hyaluronic acid [HA] derivatives) have 
durations of effect of up to one year. Long-acting agents 
(calcium hydroxylapatite [CaHA], injectable poly-L-lactic 
acid [PLLA]) have durations of effect of one to two years. The 
effects of the one currently available permanent dermal filler 
(polymethylmethacrylate [PMMA] microspheres for injec-
tion) lasts for several years and may persist indefinitely.
Short-acting dermal fillers
The short-acting dermal filler category encompasses 
bovine and cell-cultured collagen of human or avian ori-
gin (Table 1).29 The most widely used collagen implants 
are bovine-derived and human-derived bioengineered 
products.24,32 Although these implants have an immediate 
effect, which may be highly desired by some patients, a small 
number of additional injections at intervals of two or more 
weeks may be needed to achieve the desired level of initial 
correction.33 The interval is likely to be longer with the 
longer-acting collagens.34
The duration of effect and uses of individual HA products 
vary on the basis of their particle size, the extent of cross-
linking, and the location of the implant (Table 1).29,31,35 These 
products have an immediate effect, but touch-up sessions 
may be needed after one to two weeks.36 The touch-up ses-
sion requires the patient to return to the office, which may 
require additional follow-up to ensure compliance.
Use of bovine-derived collagen necessitates an intradermal 
skin test, performed at least four weeks before the desired 
procedure, to screen for hypersensitivity reactions.37,38 If the 
response is equivocal, a second test should be performed and the 
patient’s reaction should be observed for another four weeks.38 
Physicians should carefully counsel patients on the reasons for 
the test and the need for careful interpretation of the results to 
ensure compliance. Testing is not needed when human-derived 
collagen implants or HA derivatives are used.32,35
In addition to following the general guidelines described 
above, patients who have received collagen implants or HA 
derivatives should avoid strenuous exercise and consumption 
of alcoholic beverages for the first 24 hours posttreatment.33,39,40 
Makeup may be applied a few hours after treatment if there are 
no complications (eg, open wounds, bleeding, or infection).33,39,40 
Patients treated with HA derivatives should be counseled to 
avoid exposure to extreme cold weather as much as possible 
until any initial swelling and redness have resolved.41
Long-acting dermal fillers
The long-acting types of dermal filler include CaHA and 
injectable PLLA. 
Calcium hydroxylapatite
CaHA is a gel suspension of microspheres that is used to 
correct a variety of deep dermal and subcutaneous defects 
(Table 1).7,26,29 The product is often injected at the dermal-
subcutaneous border.2,26 People considering this approach 
should be advised that follow-up treatment and periodic 
maintenance treatments may also be needed.26 Patients should 
also be counseled that although the effect of CaHA injection 
appears to be immediate, some of this may appear to diminish 
during the first week as the initial swelling in response to the 
injection subsides.42
During the treatment session, massage of the treated area 
may be required to ensure that CaHA is distributed evenly, 
but following treatment with CaHA, patients should avoid 
significant movement or massage of the treated area and 
should not apply makeup for approximately 24 hours.26 If 
nodules develop, the patient should be advised to return 
quickly for puncture and expression of the contents.7 CaHA 
is a radiopaque substance that is visible on computed tomog-
raphy and x-ray scans, although it has a lower radiodensity 
than bone or teeth.7,26 Therefore, before undergoing imaging 
studies, patients should inform health care providers if they 
have received this product.26
injectable poly-L-lactic acid
Injectable PLLA was recently approved by the US Food and 
Drug Administration for use in immune competent people as 
a single regimen for the correction of shallow to deep naso-
labial fold contour deficiencies and other facial wrinkles in 
which deep dermal grid pattern injection technique is appro-
priate.28 Injectable PLLA is a polymeric device containing 
microparticles of PLLA with carboxymethylcellulose and 
mannitol which, unlike other dermal fillers, must be recon-
stituted with sterile water (5 mL) for injection before use.23 
The reconstitution time of at least two hours but not more 
than 72 hours may give rise to challenges for physicians who 
are planning treatment sessions, especially with the longer 
reconstitution times recommended by some investigators.8,23 
Depending on the area to be treated, the product should be Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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injected into the deep dermis or subcutaneous layer, but 
avoiding superficial injection.8,27,43
Patients who are considering treatment with injectable 
PLLA should be counseled that the product has a gradual 
onset of effect that occurs over several treatment sessions.43,44 
Three sessions is the average number in immune competent 
subjects, and treatments should be scheduled a minimum of 
three weeks apart.45 Subjects may require an interval between 
treatments of at least four to six weeks to minimize the pos-
sibility of overcorrection.43,44 Patients typically experience 
some degree of edema associated with the injection procedure 
that gives the appearance of a full correction by the end of the 
session, but this edema typically subsides in several hours to 
several days.27,46
After treatment with injectable PLLA, massage is an 
integral component of the injection procedure and post-
treatment care.46 Physicians should massage the treated area 
immediately after injection to distribute the product evenly, 
and they should counsel patients to continue to massage 
the treated area for three to five minutes two or three times 
daily for at least three days postinjection to promote a more 
natural-looking correction.8,46 Patients may apply makeup a 
few hours after treatment if no complications are present.27
Permanent dermal filler
The only currently available permanent dermal filler is an 
implant consisting of nonresorbable PMMA microspheres 
(Artefill®, Table 1)47 suspended in a water-based bovine col-
lagen carrier that also includes lidocaine hydrochloride.48 The 
product requires deep dermal placement.47 Successful implan-
tation results in subdermal strands that form a support structure 
beneath the wrinkle, preventing further wrinkling.47,48
People considering treatment with this product should 
be counseled that although results are immediate, repeated 
implantations at intervals of two or more weeks may be 
necessary until optimal results are achieved.47 Because the 
PMMA microspheres are suspended in a carrier gel that 
contains bovine collagen, an immunogenicity test is required 
four weeks before treatment.47 Before treatment, patients 
must be counseled that the effects will not diminish over 
time and that injected PMMA may become visible if facial 
volume changes occur as the patient continues to age.30 Since 
the implant cannot be removed easily, the permanence of 
PMMA may be problematic if the patient becomes dissatis-
fied with the results of treatment.30 As noted above, initial 
treatment with a short- or long-acting dermal filler can help 
patients fully assess whether they desire permanent changes 
to their appearance.30,31
For the first three days after treatment with injectable 
PMMA, patients should be counseled to avoid extreme facial 
expressions, because such activity may push the PMMA 
more deeply into the subcutaneous layer and compromise 
the benefits of treatment.30 Application of clear tape to the 
treated area can help to reduce facial mobility.48
Adverse reactions  
to injectable dermal fillers
Injectable dermal fillers are generally safe and well 
tolerated.49,50 Inconsistent reporting precludes an accurate 
comparison of the AE profiles of the different injectable 
dermal fillers. Most AEs associated with these products occur 
shortly after injection and are localized, mild, and transient.8 
Using a moisturizer or Vaseline® on the skin creates a smooth 
surface that can be helpful, but anti-inflammatory creams 
are not recommended. Only a very small percentage of AEs 
have a long-term detrimental impact on patients’ appearance. 
However, because enhancing appearance is the usual motiva-
tion for seeking injectable filler treatment, the appearance of 
visible AEs may be particularly distressing to the patient.2
Minor AEs that occur within the first 14 days after   treatment 
with injectable dermal fillers include skin   discoloration, swell-
ing, bruising, tenderness, and pain (Table 2).2 Bruising tends 
to be especially severe in patients treated with blood-thinning 
medications or dietary supplements with blood-thinning 
properties.2 Careful assessment of all medications/supple-
ments during the initial counseling stages can help reduce the 
risks. Swelling and tenderness are usually more pronounced 
in patients treated with longer-  acting fillers than in those who 
receive short-acting products.2
Hematoma is an uncommon event that results from inadver-
tent laceration of small facial blood vessels.2 Early infection is 
a rare event that typically is caused by the herpes simplex virus 
or common skin pathogens, such as Staphylococcus aureus.2 
These are of particular concern because they may result in 
long-term pigmentary changes or small punctate scars.2 Papules 
may result from injections that are excessive or placed too 
superficially.49 Although papules may resolve with massage, 
they can persist for several months if a long-acting filler has 
been used.2 The risks of each of these AEs can be minimized by 
careful attention to the injection technique. In addition, patients 
should be advised to avoid nonsteroidal anti-inflammatory 
drugs and omega-3 supplementation for two weeks prior to 
treatment. The physician should apply pressure immediately if 
a bruise forms, and cool packs should be applied intermittently 
for up to 24 hours after treatment. Severe but rare AEs include 
anaphylactic reactions, skin necrosis, blindness, and death.29Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 2 Frequency (%) of local adverse events occurring within the first 14 days posttreatment with widely used dermal fillersa,b
Filler type Product Redness Swelling/edema Bruising Pain/tenderness Papules
Short-acting
  Bovine collagen Zyderm 1 and 2 (3.5%  
and 6.5% dermal collagen)
,1 ,1 ,1 ,1 20 
(Zyderm® 2)
Zyplast (3.5% cross-linked 
collagen)c
60 40 29 22 20
  Cell-cultured collagen Cosmoderm (35 mg/mL 
collagen)39,d
NR NR NR NR NR
Cosmoplast (35 mg/mL  
cross-linked collagen)39,d
NR NR NR NR NR
    Avian-derived  
hyaluronic acids
Hylaform (hylan B gel)40 63 35 41 32 2341
Hylaform Plus41 74 53 44 53 (pain) 
20 (tenderness)
26
    Bacterial-cultured 
hyaluronic acids
Juvéderm® Ultra Plus36 76 71 54 84 52
Perlane61 61.3–83.7 80.7–90.8 49.3–86.5 68.7–80.9 (pain) 
86.7–92.2 (tenderness)
NR
Restylane62 84.8 87 52.2 57.2 (pain) 
77.5 (tenderness)
NR
Long-acting Radiesse (calcium 
hydroxylapatite  
microspheres)26
36.1 49.2 57 53.4 NR
Sculptra (injectable  
poly-L-lactic acid)27,d
NR NR NR NR NR
Permanent Artefill® (polymethyl- 
methacrylate 
microspheres)47,d
NR NR NR NR NR
aAdapted with permission from Carruthers J et al 2009. Copyright © 2009 Journal of Drugs in Dermatology. bSource data derived from product information unless otherwise 
noted.  cvalues derived from Hylaform trial comparator data, except lumps values, which were derived from Cosmoderm product information.  dAdverse events are not 
reported by duration in the product information for cell-cultured collagen products (Cosmoderm and Cosmoplast), injectable poly-L-lactic acid (Sculptra), and injectable 
polymethylmethacrylate microspheres (Artefill). 
Abbreviation: NR, not reported.
Delayed AEs associated with dermal fillers include 
  bacterial infections, sterile abscesses, implant migration, 
nodules, and granulomas.2 Nodules are visible or nonvisible 
structures that typically arise several weeks after the injection 
of a product that is intended to be injected into the mid dermis 
or deeper.2,46,51 They consist of fluid droplets or micropar-
ticles surrounded by a normal foreign body reaction and are 
distinguished by their indurated nature and separation from 
the surrounding soft tissue.46 They tend to remain the same 
size until they are absorbed, treated, or removed.46 Nodules 
are believed to result from improper placement of a dermal 
filler, uneven distribution of the product in its suspension, 
or uneven dispersal in injected areas.46,52
Nodules can arise within several weeks of most inject-
able dermal filler treatments,31,49,53 especially when the 
filler is injected too superficially.2 Such nodules usually 
represent product clustering at a few well-defined locations 
and can be treated using a 25-gauge needle to break them 
up, injecting the area with sterile water, and performing 
aggressive massage.46,52 In contrast, nodules that appear 
several months after injection may require treatment with 
an intralesional   injection of   triamcinolone, 5-fluorouracil, or 
  methylprednisolone   administered every one to two weeks, 
plus daily systemic therapy with low-dose prednisolone, 
doxycycline, or tetracycline.52 Nodules that fail to respond 
to more conservative treatment can be excised if they are 
large enough to warrant the procedure.46,52 Conscientious 
postinjection massage by physicians and patients may reduce 
the risk of developing nodules.8,52
Granulomas may develop throughout the treated area, 
often many months to years after treatment with any 
  dermal filler.46,54–59 The estimated incidence of granulomas 
is 0.1%–0.2%.2,46 Granulomas usually have poorly defined 
borders and are characterized by erythema, edema, and a 
violet color resulting from the presence of many congested 
capillaries.46 Untreated granulomas may grow, although they 
sometimes resolve spontaneously.46 The etiology of granu-
lomas is unknown, but it is possible that trauma, surgery, 
or another stressor may stimulate macrophages to induce 
a foreign-body reaction.46 It has also been suggested that Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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  bacteria introduced during or after the initial injection may 
cause a low-grade chronic infection with ensuing fibrosis 
and the eventual development of a granuloma.60 Intralesional 
steroid therapy, with or without an immunomodulator, is first-
line treatment for granulomas.8,46 Intense pulsed light may be 
useful in the treatment of engorged capillaries.46 Excision is 
not usually feasible, both because granulomas lack distinct 
borders and because removal attempts may result in fistulas, 
abscesses, and scars.46
No formal studies of the incidence of nodules and granu-
lomas and the factors that influence their formation were 
identified in the literature. However, in the author’s clinical 
experience, it appears that patients are exposed to a lower 
risk of AEs when careful attention is paid to the details of 
injection preparation, technique and site, patient counseling 
on proper posttreatment care, and patient adherence to guid-
ance provided during the counseling session.
Conclusion
Injectable facial volume replacement products have become 
an integral part of aesthetic cosmetic approaches. Optimal 
results with dermal fillers depend on thorough training, 
effective patient screening, and careful product selection 
and placement. Patient counseling and education by the 
physician about the procedure as well as consistent adher-
ence to pretreatment and posttreatment self-care practices 
by the patient are critical for optimal results. Motivated 
patients who demonstrate good adherence to physicians’ 
instructions generally respond well to volume replacement 
treatments and usually experience fewer AEs than those 
who are not so motivated. While promoting adherence to 
pretreatment and posttreatment protocols remains a chal-
lenge, patient counseling throughout the treatment process 
can lead to successful results. Additional research in this 
area is warranted.
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